Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
COVID-19
Interventions
DRUG

Degarelix

Degarelix is an FDA-approved drug for prostate cancer

OTHER

Saline

09% Saline

Trial Locations (14)

10010

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York

11209

Brooklyn Campus of the VA NY Harbor Healthcare System, Brooklyn, NY, Brooklyn

19106

Philadelphia MultiService Center, Philadelphia, PA, Philadelphia

33125

Miami VA Healthcare System, Miami, FL, Miami

38104

Memphis VA Medical Center, Memphis, TN, Memphis

63106

St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis

75216

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas

77030

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

85012

Phoenix VA Health Care System, Phoenix, AZ, Phoenix

90073

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, Los Angeles

90822

VA Long Beach Healthcare System, Long Beach, CA, Long Beach

98108

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

72205-5484

Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock

29401-5799

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT04397718 - Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | Biotech Hunter | Biotech Hunter